EyeGene Inc.
Financials
Valuation Metrics
EyeGene Inc.'s Market Cap is ₩840B. At end of 2025 it was ₩752B. Ranked #1382 of 2,421 in KR market (top 57%), #780 of 1,640 on KOSDAQ (top 48%), #149 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 65%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 84.04B KRW | KR#1,382/2,421 Sec#149/231 |
| Revenue | 4.48B KRW | KR#2,347/2,421 Sec#199/231 |
| Net Income | -21.03B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 68.05B KRW | KR#2,032/2,421 Sec#171/231 |
| Net Assets | 54.25B KRW | KR#1,856/2,421 Sec#157/231 |
| Employees | 50 | KR#2,050/2,421 Sec#189/231 |
| Value | ||
| P/B | 1.55x | KR#1,787/2,421 Sec#125/231 |
| P/S | 18.75x | KR#2,333/2,421 Sec#183/231 |
| FCF Yield | -7.24% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -38.76% | KR#2,237/2,421 Sec#189/231 |
| ROA | -30.90% | KR#2,322/2,421 Sec#202/231 |
| Op. Margin | -276.19% | KR#2,346/2,421 Sec#192/231 |
| Revenue Growth | 13.04% | KR#762/2,421 Sec#72/231 |
| Financial Health | ||
| Debt Ratio | 25.43% | KR#490/2,421 Sec#58/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -6.08B KRW | KR#1,553/2,421 Sec#124/231 |
| Cash | 10.19B KRW | KR#1,681/2,421 Sec#143/231 |
| Current Ratio | 3.97x | KR#393/2,421 Sec#60/231 |
| Performance | ||
| 1Y Return | -14.92% | KR#1,111/2,421 Sec#72/231 |
| 1M Return | 7.11% | KR#623/2,421 Sec#43/231 |
| From 52W High | -30.70% | KR#547/2,421 Sec#33/231 |
| 1Y MDD | -53.33% | KR#1,140/2,421 Sec#94/231 |
| Trading | ||
| Volume | 42,366 shares | KR#1,215/2,421 Sec#120/231 |
| Trading Value | 82.0M KRW | KR#1,643/2,421 Sec#163/231 |
| Foreign Own. | 1.71% | KR#1,749/2,421 Sec#168/231 |
| Per Share | ||
| EPS | -486 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,255 KRW | KR#2,249/2,421 Sec#203/231 |
Company Info
Eyegene, a bio venture founded in 2000 for proteomics and immunology research, established mRNA subsidiary Renaim and operates EyeGene Australia in 2021. The company's core focus is developing mRNA vaccines and AAV gene therapies, with gene and cell therapies at its center, having completed Phase 1/2a clinical trials for a COVID-19 preventive vaccine. It collaborates with five domestic and international companies on next-generation mRNA vaccine development and prioritizes technology acquisition through revenue-generating business and venture enterprise investments. Eyegene is headquartered in Uiwang-si, Gyeonggi-do.